So, Dr. O'Connor, what are some of the approaches that you're familiar with and working with to try to make rituximab work better? Because, as we know, that's a good, good agent, but we want to make it better.
OWEN O'CONNOR, MD: Well, this is a particularly exciting area of lymphoma research and drug development, and using the same rationale that pioneers in cancer chemotherapy have used years ago by trying to combine different kinds of chemotherapy drugs, we now have a lot of new tools, new biologic drugs like rituximab, and a lot of new molecules and drugs that are coming out related to rituximab. And so now some of the new strategies, whether it's trying to combine biological drugs in the same way that we combined chemotherapy drugs in the past to try to produce even better results.
JOHN LEONARD, MD: So, Dr. Coleman, what is your take on some of the new other monoclonal antibodies? In particular, they target all of these CDs, which can be very confusing to patients to keep track of.
MORTON COLEMAN, MD: Well, I think maybe it's important for us to sort of define what we mean by antibodies and CD20s and CD80s and so forth. An antibody should be viewed as really a guided missile directed toward the lymphoma cell. But the monoclonal antibody does not go directly to the cell in general. It goes to a specific target on the lymphoma cell, and that specific target is called an antigen.
